Omega-3 API maker KD Pharma snaps up U.K. manufacturing site for undisclosed price

Pills and vitamins
The company said the acquisition will allow it to expand capacity for producing omega-3 intermediates used in the manufacture of APIs. (Steven Depolo/CC BY 2.0)

KD Pharma, a Swiss API maker of omega-3 products, has snapped up a manufacturing site in Seal Sands, U.K., for an undisclosed price.

The company said the acquisition will allow it to expand capacity for producing omega-3 intermediates used in the manufacture of APIs. The Seal Sands facility was previously used to make omega-3 products.

KD Pharma, which employs about 400 people globally, has seven sites situated in the U.K. and U.S. The company makes omega-3 fatty acid products that are used in finished products like soft gel capsules and bottled liquid forms of pharmaceutical products.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

“The acquisition expands our technology and manufacturing base for producing APIs with the highest concentrations of EPA and DHA omega-3s,” Oscar Groet, KD Pharma’s chief executive, said in a statement. “The breadth of our technology platform sets KD Pharma apart, no company has more technologies for isolating and fractionating lipids.”

The Seal Sands plant is expected to be up and running for KD Pharma by the end of the year. The company’s other sites include Bexbach, Germany, Brattvagm, Norway and Miami.

Read more on

Suggested Articles

Akorn has been slammed with another FDA warning letter even as it is in the process of renegotiating its loans with lenders.

A manufacturing facility that Novartis discarded because of declining generics sales is getting a new life producing CBD products.

The FDA has raised questions about the manufacturing of Glenmark's new molecular entity Ryaltris, a nasal spray for seasonal allergic rhinitis.